Skandinaviska Enskilda Banken AB publ Sells 1,490 Shares of McKesson Corporation $MCK

Skandinaviska Enskilda Banken AB publ reduced its position in shares of McKesson Corporation (NYSE:MCK) by 1.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 121,756 shares of the company’s stock after selling 1,490 shares during the period. Skandinaviska Enskilda Banken AB publ owned approximately 0.10% of McKesson worth $94,061,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. J.W. Cole Advisors Inc. boosted its holdings in shares of McKesson by 35.3% during the 3rd quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock valued at $3,931,000 after acquiring an additional 1,329 shares in the last quarter. Private Wealth Partners LLC raised its position in McKesson by 5.6% in the third quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock valued at $24,598,000 after purchasing an additional 1,682 shares during the last quarter. AlphaQuest LLC boosted its stake in shares of McKesson by 91.2% during the third quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock valued at $1,365,000 after purchasing an additional 843 shares in the last quarter. CW Advisors LLC grew its holdings in shares of McKesson by 282.5% during the second quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock worth $8,067,000 after purchasing an additional 8,130 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in shares of McKesson by 12.4% during the third quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock worth $255,438,000 after purchasing an additional 36,451 shares during the last quarter. 85.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity at McKesson

In related news, EVP Thomas L. Rodgers sold 276 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the sale, the executive vice president directly owned 2,268 shares of the company’s stock, valued at $1,851,096.24. The trade was a 10.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $955.00, for a total value of $313,240.00. The SEC filing for this sale provides additional information. Company insiders own 0.08% of the company’s stock.

McKesson Trading Up 1.9%

Shares of MCK opened at $933.75 on Tuesday. The firm’s fifty day simple moving average is $842.86 and its two-hundred day simple moving average is $790.27. McKesson Corporation has a 12 month low of $585.22 and a 12 month high of $971.93. The stock has a market capitalization of $114.38 billion, a P/E ratio of 26.86, a price-to-earnings-growth ratio of 1.50 and a beta of 0.40.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping the consensus estimate of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The firm had revenue of $106.16 billion during the quarter, compared to analyst estimates of $105.98 billion. During the same period last year, the company posted $8.03 EPS. The business’s quarterly revenue was up 11.4% on a year-over-year basis. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, research analysts predict that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, March 2nd. McKesson’s dividend payout ratio is presently 9.43%.

Wall Street Analyst Weigh In

MCK has been the subject of a number of research reports. Barclays assumed coverage on shares of McKesson in a report on Monday, December 8th. They issued an “overweight” rating and a $960.00 price objective for the company. Mizuho raised their price target on shares of McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a research note on Thursday, February 5th. TD Cowen boosted their price objective on shares of McKesson from $1,000.00 to $1,012.00 and gave the stock a “buy” rating in a research note on Thursday, February 5th. Zacks Research downgraded McKesson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 25th. Finally, JPMorgan Chase & Co. lifted their target price on McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, McKesson presently has an average rating of “Moderate Buy” and a consensus price target of $937.07.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.